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Abstract
Background: Objective: To determine the relative effectiveness of evidence-informed practice using two high
compression systems: four-layer (4LB) and short-stretch bandaging (SSB) in community care of venous leg ulcers.
Design and Setting: Pragmatic, multi-centre, parallel-group, open-label, randomized controlled trial conducted in 10
centres. Cognitively intact adults (≥18 years) referred for community care (home or clinic) with a venous ulceration
measuring ≥0.7cm and present for ≥1 week, with an ankle brachial pressure index (ABPI) ≥0.8, without medication-
controlled Diabetes Mellitus or a previous failure to improve with either system, were eligible to participate.
Methods: Consenting individuals were randomly allocated (computer-generated blocked randomization schedule)
to receive either 4LB or SSB following an evidence-informed protocol. Primary endpoint: time-to- healing of the
reference ulcer. Secondary outcomes: recurrence rates, health-related quality of life (HRQL), pain, and expenditures.
Results: 424 individuals were randomized (4LB n = 215; SSB n = 209) and followed until their reference ulcer was
healed (or maximum 30 months). An intent-to-treat analysis was conducted on all participants. Median time to
ulcer healing in the 4LB group was 62 days [95% confidence interval (CI) 51 to 73], compared with 77 days (95% CI
63 to 91) in the SSB group. The unadjusted Kaplan-Meier curves revealed the difference in the distribution of
cumulative healing times was not significantly different between group (log rank c2 = 0.001, P = 0.98) nor ulcers
recurrence (4LB, 10.1%; SSB, 13.3%; p = 0.345). Multivariable Cox Proportional Hazard Modeling also showed no
significant between-bandage differences in healing time after controlling for significant covariates (p = 0.77). At 3-
months post-baseline there were no differences in pain (no pain: 4LB, 22.7%; SSB, 26.7%; p = 0.335), or HRQL (SF-12
Mental Component Score: 4LB, 55.1; SSB, 55.8; p = 0.615; SF-12 Physical Component Score: 4LB, 39.0; SSB, 39.6; p =
0.675). The most common adverse events experienced by both groups included infection, skin breakdown and
ulcer deterioration.
Conclusions: The Canadian Bandaging Trial revealed that in the practice context of trained RNs using an evidence-
informed protocol, the choice of bandage system (4LB and SSB) does not materially affect healing times, recurrence
rates, HRQL, or pain. From a community practice perspective, this is positive news for patient-centred care allowing
individual/family and practitioner choice in selecting compression technologies based on circumstances and
context.
Trial registration: clinicaltrials.gov Identifier: NCT00202267
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Background
Community care of individuals with chronic wounds has
become an important issue for home care authorities as
they deal with a growing demand for wound care in the
community. In Canada, the impact of caring for indivi-
duals with leg ulcers is only now being recognized due
to the increased pressure on the home care environment
caused by nursing shortages and tightening of healthcare
budgets [1]. In the UK, Luker and Kenrick estimated
that up to 13% of community nurses’ time was spent in
leg ulcer care [2], and more recently NHS leg ulcer
treatments (bandages and dressings) were reported to
cost £300-600 million per annum in England [3]. Our
previous work in one Ontario region demonstrated that
192 people with leg ulcers received on average 12 home-
care visits per month, and expenditures for supplies and
nursing visits were estimated at $1.3 million per annum
[4]. While there are no national data, it is reasonable to
believe that leg ulcer care in Canada consumes hun-
dreds of millions of dollars annually.
For individuals with leg ulcers, the condition has a
profound impact on quality of life [5-7]. It is chronic,
may take years to heal, 66% of individuals experience
recurring ulceration and 45% have a history dating back
ten years [8]. Studies using the Short Form (36) Health
Survey (SF-36®) instrument to measure health-related
quality of life (HRQL) have demonstrated that indivi-
duals with leg ulcers have lower mean scores than Cana-
dian population norms [9-11]. Multiple studies
document the discomfort with venous leg ulcers, with
the prevalence of pain estimated to be between 48-96
percent [12-23].
Best practice recommendations, supported by high
level evidence, indicate that the most effective treatment
for venous leg ulcers is high compression bandaging
[24-36] applied by well-trained healthcare professionals
[37-40]. However the initial Cochrane review had little
evidence about the comparative effectiveness of the
available types of high compression [41,42]. This is an
issue given there are substantive clinical, practical and
economic differences in the classes of compression tech-
nology. Early trials of bandaging systems were methodo-
logically weak due to factors such as being
underpowered [25]. By 2000 the VenUS I trial [43] was
underway in the UK to determine the relative effective-
ness of two of the most popular high compression sys-
tems, ‘four-layer’ (4LB: strictly speaking a four-
component bandage system) and short-stretch banda-
ging (SSB). As the effectiveness and costs of the com-
pression systems are likely related to service delivery
and bandaging skills, we realized that the UK trial
would not be able to completely answer the question for
the Canadian healthcare system. In 2002, a Canadian
team, working with the leads of VenUS I (Drs. E.A.
Nelson and N. Cullum), set out to conduct a concurrent
trial to provide more data about clinical and cost-effec-
tiveness of the high compression technologies since the
results of available published trials (Duby, Scriven,
Partsch: n = 226 participants) were equivocal [44-46].
The Canadian trial, funded by the Canadian Institutes of
Health Research (CIHR), was launched in 2004. Cana-
dian homecare authorities were interested in a compari-
son of these commonly available bandaging systems
based on a health services outcome, i.e. a 4-week differ-
ence in healing based on known costs of delivering the
technologies in Canada. Thus, the purpose of this Cana-
dian trial was to compare healing rates between two
bandaging technologies, specifically: 1) determine if
healing occurred at least 4 weeks earlier with SSB vs.
4LB; 2) assess related outcomes such recurrence rates,
HRQL, pain, and adverse events over a one-year follow-
up; and 3) identify potential baseline factors that predict
healing.
Methods
The Canadian Bandaging Trial (CBT) was a multi-centre
parallel-group, randomized controlled trial conducted in
10 centres in three provinces. Recruitment involved all
individuals referred for community wound care services
(homecare or nurse clinic) with new, existing or recur-
rent venous ulceration. Ethics approval for the trial was
received from Queen’s University Research Ethics Board,
Kingston Canada (REB# NURS-140-03).
Study population
Individuals in community care were eligible for inclu-
sion based on the following: adult (≥18 years), English-
speaking or with access to translation, able to provide
written informed consent, clinical presentation of
venous insufficiency with an ankle brachial pressure
index (ABPI) ≥0.8, and a leg ulcer with minimum dura-
tion of one week that measured at least 0.7 cm in any
one dimension. After conducting a small pilot study, the
eligibility criterion was changed from having an ulcer of
at least 1 cm in any one dimension to 0.7 cm since it
was found that too many individuals were being
excluded that would have normally been treated with
compression. Exclusion criteria were: medication-con-
trolled diabetes mellitus, failure to improve over a 3-
month period with either bandaging system prior to the
trial, previous enrollment in the trial, and cognitive
impairment.
Procedures
All participating study sites were supported to develop
their evidence-informed protocols for venous leg ulcer
management during the preliminary and pilot phase of
this enquiry [47]. Protocol development is described
elsewhere [10,48] but in brief, the local protocol was
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developed from guideline recommendations using a sys-
tematic 10-step adaptation process [49,50]. Training was
provided on the use of both SSB and 4LB technologies
and site investigators conducted random audits of pro-
tocol delivery to ensure ongoing compliance.
Upon referral for leg ulcer care, individuals received a
comprehensive, standardized clinical assessment by spe-
cially trained registered nurses (RNs). Individuals were
informed of the study and invited to participate. Con-
senting individuals were randomly allocated by research
staff, available 7 days/week over day and evening hours
via a remote telephone service, to receive one of two
high compression technologies; 4LB or SSB. A compu-
ter-generated blocked randomization schedule was used
to allocate participants. Allocation was sealed in opaque,
serially numbered envelopes. Randomization was con-
trolled centrally from the university research office and
stratified by centre, ulcer size (≤ 5 or > 5 cm2), ulcer
duration (≤ 6 or > 6 months), and whether they had a
previous ulcer, as these factors may influence healing
rates [51,52]
Intervention: High Compression Bandages
The 4LB system (control arm) was originally developed
in the UK (Charing Cross Hospital) [53]. The commer-
cial product widely used in Canada is Profore® (Smith
& Nephew Medical Ltd.). Precise components of the
4LB depend on the ankle circumference [54]. Bandages
can remain in situ for up to one week (e.g. if minimal
wound exudate) with bandages being changed when
required. Bandages were discarded after each use.
Cotton short-stretch bandages (SSB) Comprilan®
(Beiersdorf-Jobst, Inc.) were applied using the modified
Putter technique [55]. Varying widths of bandage, e.g., 8
cm, 10 cm and 12 cm, were used according to the width
of the limb. A layer of orthopedic wool padding was
applied beneath the bandage to distribute the compres-
sion evenly. Bandages were changed when required, as
determined by the attending nurse. Participants washed
and reused the short stretch wherever possible. For both
4LB and SSB, bandaging continued until the affected
limb completely healed.
Data Collection and Management
Baseline data collection began at the time of initial
assessment through interview, clinical assessment and
chart review. Socio-demographic and clinical assess-
ment, and measurements of primary and secondary out-
comes were completed at baseline. Monthly, the
participant’s reference ulcer (defined as the largest ulcer
at randomization) was traced onto acetate to measure
the wound surface. Adverse events and referrals to spe-
cialists were recorded. A Participant Satisfaction Survey
was administered one month post-baseline or at healing
(whichever came first) to capture patients’ perspectives
of their allocated bandage treatment and health services
received. Economic data were also recorded and a report
is in preparation. Study participants were followed until
their reference leg ulcer was healed or for a maximum
of 30 months until March 31, 2009. After healing, fol-
low-up continued for one year to assess durability of
healing.
Quality assurance procedures [56-58], included a
detailed protocol manual for the site study teams and a
log record to track the status of participants throughout
the duration of the trial. Participants were assigned a
unique identifying number used on study documenta-
tion to ensure confidentiality. Withdrawals from either
arm of the study were monitored and reasons documen-
ted. Case records (10%) were randomly selected to
assess data entry accuracy every 3 months.
Primary and secondary outcomes
The primary endpoint was time (weeks) to complete
healing of the reference ulcer. A healed ulcer was
defined as fully epithelialized; no scab remaining, and no
drainage. The point of healing was confirmed by: 1)
serial tracing of the leg ulcer and 2) photographing the
ulcer at the time of healing which was verified by a
remote researcher, masked to allocation (EAN). Second-
ary outcomes included recurrence rates, HRQL, pain,
and expenditures over a one-year follow-up. Adverse
events related to the bandages were tracked.
Sample size calculation
Our trial was adequately powered to detect whether the
median healing time of SSBs is 4-weeks shorter than
that of 4LBs. Sample size calculation was based on time-
to-healing. Using local research on leg ulcer healing and
service delivery [10,48], and the largest available trial at
the time comparing 4LB and SSB (Partsch 2001, n =
112) [45] it was postulated that the median time to heal-
ing with 4LB would be 16 weeks. To determine the
minimally important difference (MID) that would war-
rant changing from 4LB to SSB as first-line therapy,
practitioners and homecare administrators were con-
sulted. The consensus was that to opt for SSB over 4LB
would be justified if no additional nursing visits were
required. Local experience showed that during the first
month of treatment with 4LB, on average 2.5 visits/week
were required, followed by ~1.5 visits/week until healing
occurred. For SSB, on average 3 visits/week were
required for the first month, then 2 visits/week there-
after until healing. Assuming a median time-to-healing
with 4LB of 16 weeks, an average 28 nursing visits
would be required. Given the higher frequency of nur-
sing visits with SSB, 28 nursing visits would occur over
12 weeks of care. Therefore, for SSB to be considered
an attractive option for Canadian homecare regions, it
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would have to demonstrate a median time-to-healing of
12 weeks or less, thus a 4-week difference in healing
was identified as the MID in time-to-healing.
With a median difference of 4-weeks in healing time
(baseline, 16 weeks), 80% power, and a 5% level of sig-
nificance, it was determined that 207 participants would
be required in each arm (414 total) allowing a 5% loss
to follow-up. A review of our previous studies’ recruit-
ment and activity status data revealed that the lost to
follow-up rate was slightly higher than 5% therefore the
sample size was increased to 424 participants.
Analysis
The primary analysis was based on ‘intention-to-treat’.
Index scores were generated for the Short Form McGill
Pain Questionnaire (SF-MPQ), and SF-12® Physical
Component (PCS) and Mental Component Summaries
(MCS) were derived using the Quality Metric SF Health
Outcomes™ Scoring algorithm [59,60]. Individual miss-
ing items for the SF-12® were imputed using assignment
of mean score (AMS) [61,62]. Following a descriptive
analysis, the baseline and clinical characteristics of the
4LB and SSB groups were compared. The primary out-
come, time-to-healing of the reference ulcer, was com-
pared between individuals randomized into the two
groups. Kaplan-Meier survival curves were constructed
for the two groups. The statistical significance of the dif-
ference between the two bandaging groups was tested
using log rank tests. Cox proportional hazards modeling
was used to identify baseline demographic and prognos-
tic indicators of time to healing, in addition to assessing
the effect of treatment group. Indicators included geo-
graphic location, sex, age, living situation, co-morbid-
ities, pain, mobility, ankle flexion, edema, ABPI, ulcer
episode, ulcer duration, and ulcer size [51,63-67]. Fac-
tors that predicted healing in bivariable analyses (p ≤
0.15) were included in the multivariable analysis. The
assumption of proportionality of hazards was tested for
all factors using log-minus-log plots. The chi-square test
was used to compare the proportion of ulcers that
recurred in the two groups. Adverse events and partici-
pants’ perceptions of the bandaging systems were com-
pared using chi-square tests. All analyses were
completed using IBM© SPSS© Statistics software (Ver-
sion 19 for Windows).
Results
Over a 50 month recruitment period (January 2004 -
March 2008), 2820 individuals referred for community
leg ulcer care were screened (see Figure 1). Many of
those referred for care did not have purely venous leg
ulcers, thus the trial procedures required a major
screening effort. For example more than half screened
had diabetic or arterial issues (hence mixed ulcer
aetiology) but there was no way of knowing this prior to
examination by the nurse and it was vital to maintain
an evidence-informed clinical assessment consistently.
Consequently only 520 were assessed as eligible with
82% of those (n = 424) agreeing to participate.
Of the 424 trial participants, 215 were randomized to
receive 4LB, and 209 to receive SSB. There were no dif-
ferences on admission between the participants rando-
mized to either bandage on their socio-demographic,
circumstance of living, HRQL or clinical characteristics
(Table 1).
Mean age of the participants was 65 years with slightly
more women (54%) than men and the majority being
English-speaking (91%). Most participants were fully
mobile and lived with others. For more than half (55%),
this was their first episode of ulceration and the median
ulcer duration at baseline was nearly 12 weeks. PCS
baseline scores were much lower than the age- and sex-
adjusted Canadian norms (39.1 vs. 51.7); indicating that
those with venous leg ulcer had much poorer physically
oriented HRQL. However, mental HRQL was better,
with MCS scores comparable to Canadian norms (51.4
vs. 50.5) [68]. There were no differences in key aspects
of the clinical care received by the two groups (Table 2).
Time-to-Healing
The median time to reference ulcer healing in the 4LB
group was 62 days [95% confidence interval (CI) 51 to
73], compared with 77 days (95% CI 63 to 91) in the
SSB group. Figure 2 shows the unadjusted Kaplan-Meier
curves. The difference in the distribution of cumulative
healing times between the two groups was not signifi-
cantly different (log rank c2 = 0.001, P = 0.98).
Factors affecting time-to-healing
Several factors were associated with time-to-healing in
bivariable analysis, however in multivariable analysis,
only age, ulcer size at baseline and geographic location,
predicted time-to-healing (Table 3).
Secondary Outcomes
The proportion of people who experienced a recurrence
of their reference ulcer after healing during the one year
follow-up was relatively small (10% for 4LB, 13% for
SSB; no statistically significant difference). At 3-months
post-baseline there were no differences in pain (no pain:
4LB, 22.7%; SSB, 26.7%; p = 0.335) or HRQL outcomes
(SF-12 MCS: 4LB, 55.1; SSB, 55.8; p = 0.615; SF-12 PCS:
4LB, 39.0; SSB, 39.6; p = 0.675) and little improvement
from the group’s low baseline values on the PCS.
Adverse Events
Adverse events were tracked up to 30 months. In both
groups the most common adverse events were infection,
skin breakdown and ulcer deterioration with 29% of the
Harrison et al. BMC Nursing 2011, 10:20
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4LB group and 33% of the SSB group experiencing an
adverse event (not significant, Table 4). The SSB group
took 2 weeks longer to heal thus, were ‘at risk’ of
adverse event occurrence for a longer period of time.
Participant Satisfaction Survey
Analysis of participants’ perceptions revealed 41% of the
4LB group reported experiencing a problem with their
bandaging compared to 28% of those allocated SSB (p =
 
 
 
 
 
Analyzed SSB (n = 209) 
Excluded from analysis (n = 0) 
Agreed to Participate 
Not venous insufficiency    (n = 1103) 
Ulcer < 0.7cm in length/width   (n=278) 
Ulcer duration less than 1 week   (n = 18) 
ABPI less than 0.8     (n = 414) 
Unable to consent/dementia   (n = 100) 
Language barrier    (n = 10) 
Diabetes mellitus    (n = 227) 
Previously failed with trial bandage  (n = 30) 
Previous trial participant    (n = 18) 
High compression contraindicated  (n = 21) 
Unable to tolerate high compression  (n = 49) 
Other*      (n = 32) 
?ABPI too high (6), Too ill (9), Physician refusal (2), Lives out of 
catchment area (4), Unusual presentation (1), Private pay client (1), 
Client homeless (1), “Previous trial patient” misunderstood (1), Put on 
different study (1), Plate and screws in place (1), “Champagne bottle” 
legs (1), Multiple allergies (1) 
Yes 
Randomized  
(n = 424) 
Allocated to 4LB (n = 215) 
   Received Allocated intervention (n = 212) 
   Did not receive allocated intervention (n = 3) 
Allocated to SSB (n = 209) 
   Received Allocated intervention (n = 209) 
   Did not receive allocated intervention (n = 0) 
Lost to follow-up/End of Trial 4LB (n = 23) 
Participant died (n = 7) 
Participant requested to leave study (n = 9) 
Participant moved out of area (n = 1) 
Unable to contact participant (n = 2) 
Other* (n = 4) 
*Cancer (3), Transferred (1) 
Discontinued use of intervention (n = 57) 
Refuses compression bandaging no other reason 
given (n =7) 
Participant admitted to hospital (n = 5) 
Ulcer area increased/not progressing (n = 1) 
Problem with bandaging (n = 36) 
Client briefly unavailable for treatment (n =3) 
Change in Doctor’s orders (n=2) 
Client put into stockings prematurely (n = 3) 
Lost to follow-up/End of Trial SSB (n = 10) 
Participant died (n = 1) 
Participant requested to leave study (n = 6) 
Participant moved out of area (n = 1) 
Unable to contact participant (n = 1) 
Other* (n = 1) 
*Cancer (1) 
Discontinued use of intervention (n = 44) 
Refuses compression bandaging no other reason 
given (n =5) 
Participant admitted to hospital (n = 2) 
Ulcer area increased/not progressing (n = 5) 
Problem with bandaging (n =20) 
Client briefly unavailable for treatment (n =5) 
Change in Doctor’s orders (n=3) 
Client put into stockings prematurely (n = 4) 
Analyzed 4LB (n = 215) 
Excluded from analysis (n = 0) 
No (96) 
Refused to participate (n = 45) 
Refused bandage    (n = 39) 
Too busy     (n = 12) 
Eligible (n = 520) Not Eligible (n = 2300) 
Screened  
(n = 2820) 
Figure 1 CBT Recruitment and Randomization.
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0.01). In particular, there was significantly greater dis-
comfort with the 4LB (p = 0.05), and participants felt it
was often applied to tight (p < 0.01). The majority in
both groups reported being very satisfied with the
nurses’ skills in applying the bandage, and reported that
the nurses provided verbal and written information
regarding ulcer care and prevention (Table 5).
Discussion
The Canadian Bandaging Trial was adequately powered
to detect a minimally important difference of 4-weeks in
Table 1 Baseline and clinical characteristics of the study population by intervention group
Characteristics1 4LB
(n = 215)
SSB
(n = 209)
p-value
Gender (female) 119 (55.3) 111 (53.1) 0.70
Language (English) 189 (87.9) 195 (93.3) 0.16
Lives with others 140 (65.1) 131 (62.7) 0.61
Fully mobile 174 (80.9) 163 (78.0) 0.47
Non-venous history 125 (58.1) 132 (63.2) 0.32
Leg ulcer pain on admission2 183 (89.7) 182 (89.2) 1.00
Medications for leg ulcer pain 53 (24.7) 62 (29.7) 0.28
# Co-morbidities
None 40 (18.6) 34 (16.3) 0.67
1 - 2 136 (63.3) 131 (62.7)
≥ 3 39(18.1) 44 (21.1)
Previous leg ulcers 93 (43.3) 98 (46.9) 0.50
Previous compression3 125 (58.4) 128 (61.2) 0.62
Reference ulcer on left leg 108 (50.2) 105 (50.2) 1.00
Edema on affected leg4 180 (84.9) 175 (84.1) 0.89
Full flexion on affected leg5 167 (79.9) 168 (82.0) 0.62
Age (years)* 64.4 (16.2) [23.8-93.0] 65.7 (17.0) [22.8-94.1] 0.41
Duration of current ulcer (weeks)† 11.7 (0.14-521.1) 11.4 (0.86-1044.7) 0.806
Area (cm2) - Tracing7† 3.0 (0.16-139.8) 3.3 (0.07-50.8) 0.746
ABPI on affected leg8* 1.05 (0.15) [0.79-1.7] 1.04 (0.15) [0.79-1.5] 0.60
McGill Pain2*
Sensory Pain Index 18.5 (18.1) 19.5 (17.4) 0.58
Affective Pain Index 6.7 (14.7) 7.5 (15.9) 0.61
Total Pain Index 15.3 (16.0) 16.3 (15.8) 0.56
PPI-VAS9 2.5 (2.3) 2.8 (2.5) 0.24
SF-1210*
Physical Component (PCS) 39.5 (10.5) 38.7 (9.2) 0.40
Mental Component (MCS) 51.9 (9.9) 50.9 (9.9) 0.34
1 Values in parentheses are percentages unless indicated otherwise; *values are mean (s.d.) [range]; †values are median (range). 4LB, four-layer bandages; SSB,
short-stretch bandages.
2 Pain data were available for 204 participants in each treatment arm
3 Previous compression data were available for 214 participants in the 4LB group
4 Data on edema and dependency edema were available for 212 participants in the 4LB group and 208 in the SSB group
5 Data on ankle flexion were available for 209 participants in the 4LB group and 205 in the SSB group
6 Mann-Whitney U
7 Ulcer tracing data were available for 206 participants in each treatment arm
8 ABPI data were available for 214 participants in the 4LB group
9 PPI-VAS; Present pain intensity - visual analogue scale
10 SF-12 data were available for 204 participants in the 4 LB group and 203 in the SSB group. Values imputed using mean for individual missing responses
Table 2 Adherence to the Evidence-Informed Protocol
Variables Four Layer
(n = 215)
Short-Stretch
(n = 209)
% (n) % (n)
Comprehensive Clinical Assessment 100 (215) 100 (209)
Doppler ABPI 100 (215) 100 (209)
High Compression Therapy
All 98.6 (212) 100.0 (209)
Venous disease 99.1 (210) 97.1 (203)
Mixed Disease 0.9 (2) 2.9 (6)
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median healing time between 4LBs and SSBs. We put
much emphasis on testing the compression technologies
within an evidence-informed approach to care i.e. a pro-
tocol for venous leg ulcer assessment and management,
well developed training procedures, and well prepared
RNs. With these elements in place, results from our
trial suggest that the two compression bandaging tech-
nologies tested are not different in terms of time-to-
healing, recurrence rates, HRQL, or pain. However, indi-
viduals were less satisfied with 4LB, with more reporting
problems with the bandaging system.
These healing results should be viewed in the context
of all the trials making this comparison. O’Meara et al.
[33] conducted a meta-analysis of individual patient data
to evaluate the intervention effect of 4LBs relative to
SSBs. They concluded that venous leg ulcers in patients
treated with 4LBs heal faster, on average, than those
treated with SSBs; and the benefits were consistent
across patients with differing prognostic profiles. In con-
trast, our trial (the largest to date), put much emphasis
on other aspects of venous leg ulcer care, namely an
evidence-informed protocol of care and well-prepared
RNs in administering these bandaging systems. With
these elements of care in place, there were no differ-
ences between the technologies except that individuals
may have more problems with 4LBs.
In the O’Meara meta-analysis, the intervention effect
estimate from the UK VenUS I was weighted heavily
towards the pooled effect estimate (i.e. 63% from this
trial among five others). As the only other large scale
trial comparable to this Canadian RCT, the UK VenUS I
showed that with 4LBs there was a shorter healing time.
We were unable to replicate this finding despite com-
parable sample sizes. Several factors may be contributing
to this difference. Nurse wound-care teams in Canada
have more training and experience in both technologies.
The SSB was newly introduced to UK primary care just
prior to their trial and there was a higher withdrawal
rate in the SSB arm of the VenUS I trial. The UK
authors [43] state they “investigated the introduction
(their emphasis) of a high-level compression bandage
system into a setting where an acceptable mode of
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Numbers at Risk of Healing
4LB Group 215 82 55 28 16 11
SSB Group 209 98 48 23 11 9
Figure 2 Kaplan-Meier curves showing proportion of ulcers healed by treatment with four-layer and short-stretch bandages.
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compression was already in use” and a reasonable con-
clusion is that short stretch is “a useful alternative” (pg.
1298). Based on the experience from the UK trial, our
Canadian sites had initial and ongoing training including
quality checks to ensure adherence to the evidence-
informed assessment and management protocol for
either bandage. In the Canadian trial, the nurses may
have been more confident and competent in delivery of
both bandage systems thus reducing operator experi-
ence/preference as a source of bias. Another context
factor may be important. Canadian site teams actively
participated in the development of the protocol in their
local settings to make it as seamless as possible within
their normal delivery of care. Based on best practice
recommendations, they carefully constructed an
approach to adhere to key aspects of leg ulcer assess-
ment and management. For example, the initial compre-
hensive assessment may have been carried out by
specially trained nurses in the home with portable
equipment whereas at some sites, it was more feasible at
a designated clinic location where a wound expert and
equipment were centralized.
In considering the site differences our team thought
there were factors that should be further explored in a
Table 3 Treatment effect on time to healing adjusted for explanatory co-variates
Bivariate Analysis Multivariate Analysis
Variable Sig. Hazard Ratio (C.I) Sig. Hazard Ratio (C.I)
Centre1 Grouping 1 < 0.01 1.0 < 0.01 1.0
Grouping 2 < 0.01 2.2 (1.6-3.1) < 0.01 1.8 (1.2-2.6)
Grouping 3 < 0.01 2.8 (2.0-4.0) < 0.01 2.3 (1.6-3.4)
Grouping 4 < 0.01 2.6 (1.8-3.7) < 0.01 2.5 (1.7-3.7)
Grouping 5 < 0.01 4.2 (3.2-5.6) < 0.01 3.7 (2.7-5.0)
Gender2 Male - 1.0 - 1.0
Female 0.34 1.1 (.90-1.4) 0.26 1.1 (.91-1.4)
Age Decades < 0.01 1.1 (1.1-1.2) 0.04 1.1 (1.0-1.1)
Living situation Alone - 1.0 - 1.0
With others 0.09 1.2 (.97-1.5) 0.08 1.2 (.98-1.5)
Co-morbidities None < 0.01 1.0 n.s.
1-2 0.06 1.3 (1.0-1.7)
> 3 < 0.01 2.2 (1.5-1.3)
Pain on Admission Yes - 1.0 n.s
No 0.02 1.5 (1.1-2.1)
Mobility Fully mobile - 1.0 n.s
Walks with assistance/immobile 0.02 1.4 (1.1-1.7)
Ankle flexion Full flexion - 1.0 n.s
Impaired/no flexion 0.10 1.3 (.96-1.6)
Edema Yes - 1.0 N/A
No 0.86 1.0 (.77-1.4)
ABPI < 0.01 5.7 (3.0-10.9) n.s
Previous Ulcer Yes - 1.0 N/A
No 0.64 1.0 (.86-1.3)
Ulcer duration ≤ 12 weeks < 0.01 1.8 (1.5-2.2) n.s
> 12 weeks - 1.0
Ulcer size ≤ 2.5 cm < 0.01 2.7 (2.1-3.5) < 0.01 2.1 (1.5-2.7)
> 2.5 to ≤ 10 cm < 0.01 1.6 (1.2-2.0) < 0.01 1.5 (1.1-2.0)
> 10 cm < 0.01 1.0 < 0.01 1.0
Allocated Bandage Four layer - 1.0 0.77 1.0
Short stretch 0.99 1.0 (.82-1.2) 1.0 (.84-1.3)
1Study centres have been concealed for anonymity and grouped by geographic region where n < 50
2Gender and Allocated Bandage were forced into the model
3For the bivariate analysis, the sample size was 424 for most variables (408 for pain on admission, 420 for edema, 423 for ABPI) and 39 cases were censored. For
the multivariable model, a total of 24 were excluded due to missing data and 36 were censored.
N/A = Variable not entered into Cox Regression (p > 0.15)
n.s. = Variable not selected for Cox Regression final model
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future study. Although we tracked key elements of the
evidence-informed protocol (comprehensive assessment
and use of compression), and all sites delivered these
recommendations, there may be subtle differences con-
tributing to healing rates. For example, some sites were
newer and less experienced and may have been less sup-
ported regionally in the delivery of care. As well,
because the trial was conducted in a large number of
jurisdictions the referral and wait-times may have varied
influencing the time to assessment which may have
affected outcomes. Unfortunately we did not have data
to drill down and explore these issues in this trial.
Lastly, healing in the Canadian trial for 4LB was 62
days compared to 77 days with SSB - both much shorter
than the UK study population. This may be partly
explained by their healing outcome being complete heal-
ing of all ulcers not just a reference ulcer. Nevertheless
in examining healing over time compared to previous
trials (Table 6), the Canadian group had higher propor-
tions healed at 12, 16, 24 and 52 week time-points for
both SSB and 4LB except SSB at 16 weeks in the
Partsch study [45].
From this large Canadian trial the key message regard-
ing healing is ‘when delivered in the practice context of
trained RNs and an evidence-informed protocol choice
of bandage system (4LB and SSB) does not materially
affect healing times, recurrence rates, HRQL, or pain’.
Expenditures and resource use should be another con-
sideration. According to results from the UK VenUS I
trial on average, 4LB was associated with greater health
benefits and lower costs than SSB. In a separate cost-
effectiveness analysis, we are addressing whether this
finding holds in the community care setting in Canada.
Table 4 Adverse events potentially related to
compression bandages (max. 30 months)
4LB
(n = 215)
SSB
(n = 209)
p-value
n (%) n (%)
Pressure damage 15 (7.0) 13 (6.2) 0.85
Skin breakdown 27 (12.6) 34 (16.3) 0.33
Ulcer deterioration 27 (12.6) 32 (15.3) 0.48
Infection 28 (13.0) 35 (16.7) 0.34
New ulcer 13 (6.0) 22 (10.5) 0.11
Allergy/dermatitis related to bandaging 15 (7.0) 14 (6.7) 1.00
Allergy/dermatitis related to ointment/
cream
9 (4.2) 10 (4.8) 0.82
Recurrence 2 (0.9) 5 (2.4) 0.28
Limb compromise 2 (0.9) 2 (1.0) 1.00
Total 138 (64.2) 167 (80.0)
Table 5 Participant’s perceptions at 1-month post-baseline of compression bandages and care received
Four-Layer
(n = 196)
Short Stretch
(n = 199)
p-value
n (%) n (%)
Reported problems with bandaging 81 (41.3) 56 (28.1) 0.01
Skin reactions 16 (8.2) 9 (4.5) 0.15
Discomfort 49 (25.0) 33 (16.6) 0.05
Skin breakdown 12 (6.1) 10 (5.0) 0.67
Applied too tight 35 (17.9) 10 (5.0) < 0.01
Applied too loose 6 (3.1) 7 (3.5) 1.00
Satisfaction with nurses’ skills applying the bandage1
Very satisfied 154 (79.0) 171 (85.9) 0.10
Quite satisfied 40 (20.5) 25.0 (12.6)
Neither satisfied or dissatisfied 1 (0.5) 1 (0.5)
Quite dissatisfied 0 (0.0) 2 (1.0)
Bandage comfort2
I have to take them off because they are too uncomfortable 13 (6.7) 8 (4.0) 0.18
I wear them but they are very uncomfortable 6 (3.1) 2 (1.0)
I wear them but they are slightly uncomfortable 47 (24.1) 41 (20.6)
I have no trouble wearing them 129 (66.2) 148 (74.4)
The nurse gave information about how to care for leg ulcer3 180 (92.3) 178 (89.4) 0.38
The nurse talked about preventing the ulcers from coming back4 161 (82.1) 164 (82.8) 0.90
The nurse gave written information about preventing the ulcers from coming back5 114 (58.2) 113 (57.7) 1.00
1Perception of nurses’ skill applying bandage data were available for 195 participants in the 4LB group
2Bandage comfort data were available for 195 participants in the 4LB group
3 Information given to care for their leg ulcer data were available for 195 participants in the 4LB group
4Verbal information given to prevent ulcer recurrence data were available for 198 participants in the SSB group
5 Written information given to prevent ulcer recurrence data were available for 196 participants in the SSB group
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Limitations of the Study
This trial has some limitations that should be considered
when interpreting the results. It might be considered a lim-
itation that nurses providing care were involved in collec-
tion of outcomes data. Blinding the nurse to the
compression technology was not feasible and once ban-
dages were applied it would have been excessively intrusive
(and monumentally expensive) to remove them solely for
the purpose of an outcome assessment. However, our small
team of dedicated specially trained nurses, ensured expert,
quality outcome assessments by measuring healing in a rig-
orous and consistent manner and this was validated by
photo assessment by an expert remote from the site of care
and who was blinded to allocation group. The results may
not be generalizable beyond the study population but since
the trial took place in multiple sites in three provinces
(Ontario, Manitoba and Saskatchewan) that included both
urban and rural locations, and culturally mixed populations
this should increase the likelihood of generalizability.
Strengths
This RCT is the largest community wound trial conducted
in Canada and the largest trial evaluating these two com-
pression technologies internationally. The trial’s pragmatic
approach emulated the usual delivery of assessment and
care with healing outcomes confirmed by an individual
blinded to study arm. The comparative effectiveness of
SSB and 4LB systems in healing ulcers will be more pre-
cisely addressed when the Canadian trial is added to the
meta-analysis from the Cochrane Wounds Group [33]
recognizing that context is important and contributing to
the sub-groups analysis of trial result by country of study.
Conclusions
Internationally this is the largest reported trial on ban-
daging systems and should immediately contribute to
body of evidence at the Cochrane Library and elsewhere.
We were unable to replicate the results of the largest
UK trial, VenUS I. Within the Canadian context, the
implications are that homecare authorities and commu-
nity providers can expect similar healing, quality of life,
pain and recurrence results from 4LB and SSB compres-
sion technologies. It is vital to note that these results
are dependent on compression bandages being delivered
within an overall approach of evidence-informed care by
well-prepared providers - this cannot be overstated.
From a community practice perspective, these results
are positive news as it allows individual/family and prac-
titioner choice in selecting a technology class based on
the circumstances and context. This means being better
able to deliver patient-centred care. Given either ban-
dage is effective, the choice can be made with indivi-
duals and practitioners based on bandage preference.
The bandage systems require different self-care ability
and supports, levels of nursing time, variation in indivi-
dual comfort, and preparation and teaching. From a pol-
icy perspective, the organization of care can be adjusted
to account for the different requirements with either
bandaging technology. If delivery of only one, or the
other, is possible because of local factors and resources,
it is important to know that the expectation of healing
would not be compromised whichever is selected. Sev-
eral next steps to advance leg ulcer care emerge from
this Canadian study, including:
• Conducting a meta-analysis to include this large
Canadian trial to the existing reports on SSBs and
4LBs to increase power and add another country’s
experience
• Analyzing the economic implications of the Cana-
dian trial for SSB and 4LB in order to position the
effectiveness results for planners and policy makers.
• Addressing the deficit in evidence for people with
diabetes who have leg ulcers. Although typically
excluded from compression trials, in practice com-
pression is used with this group. Healing rates and
other outcomes are unknown (people with diabetes
comprised ~24% of those excluded in this trial). We
suggest the conduct of a pragmatic trial using a
similar approach (qualified team, evidence-informed
protocol).
• Research to integrate the multiple possible wound
outcomes into administrative databases is needed to
reduce the need for primary data collection for
costly follow-up in large scale studies. In particular
recurrence rates are clinically and administratively
important but add enormously to trial costs. Issues
include the organization, accessibility and quality of
data currently collected in the community and home
care environment. Chronic wounds e.g. leg ulcers
Table 6 Healing Rates at 12, 16, 24, and 52 weeks in
trials comparing four-layer and short-stretch bandages
Proportion of Ulcers Healed (%)
12 Weeks 16 Weeks 24 Weeks 52 Weeks
Reference Year 4LB SSB 4LB SSB 4LB SSB 4LB SSB
Duby et al. * 1993 44 40 - - - - - -
Scriven et al. * 1998 34 41 - - - - 53 56
Partsch et al. † 2001 - - 62 73 - - - -
Ukat et al. 2003 30 22 - - - - - -
VenUS I† 2004 46 37 55 45 68 55 78 72
Franks et al. † 2004 - - - - 69 73 - -
Harrison et al. 2011 58 53 67 63 69 75 83 92
*In these trials the legs of several patients with bilateral ulceration were
randomized independently. †Primary outcome in these trials was complete
healing of all ulcers on trial leg (in the presence of multiple ulcers this would
tend to underestimate the outcome of ulcer healing). 4LB, four-layer
bandages; SSB, short-stretch bandages.
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(arterial and venous), diabetic and pressure ulcers,
are increasingly being cared for in the community.
Future wound studies would all be aided by
improved administrative tracking of outcomes.
• Given the self-management aspects with compres-
sion bandages, research into the supportive care
needed for self-management is an important area for
enquiry.
In conclusion the Canadian bandaging trial adds new
information to the international literature focused on
the management of leg ulcers in the community. Two
commonly available technologies, short-stretch and
four-layer bandages, are viable options that result in
similar healing, recurrence, HRQL and pain outcomes
when delivered by trained nurses using an evidence-
informed protocol.
Other information
Registration
This trial is registered at http://www.clinicaltrials.gov,
identified by number NCT00202267.
Protocol
The full trial protocol is not publicly available at this
time.
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